Chroma Therapeutics Advances Novel Targeted Agent Towards Clinical Development; Receives Milestone Payment And Extends Collaboration With GSK
3rd January 2013

Final Opal Phase II Results Of Tosedostat Demonstrate Significant Response Rates In Elderly Patients With Treatment Refractory Or Relapsed Primary Or Secondary Acute Myeloid Leukemia
13th December 2011

Chroma announces new positive Interim Phase II data for Tosedostat in AML OPAL study, revealed at ASCO
8th June 2011

New Tosedostat Data Selected For Oral Discussion Session At The 2011 Asco Annual Meeting
24th May 2011

Chroma Therapeutics and Cell Therapeutics Enter into a Collaboration to Develop and Commercialise Tosedostat, a First in Class Tumour Selective Oral Anti-Cancer Therapy
15th March 2011

Chroma Therapeutics to present at 29th annual J.P. Morgan Healthcare Conference
6th January 2011

Chroma Therapeutics Advances Novel Targeted Agent Into Development; Receives Milestone Payment from GSK
24th August 2010

Chroma Strengthens Its Board Through The Appointment Of Goran Ando As Non-Executive Director; Appoints Prof. Paul Workman As Head Of Scientific Advisory Board
25th May 2010

Chroma and GSK enter into major collaboration to discover macrophage-targeted drug
23rd June 2009

Chroma raises £15 million in Series D financing
23rd June 2009

Chroma Announces Positive Phase II Efficacy Data For Novel Cancer Therapy Tosedostat In Acute Myeloid Leukaemia
11th December 2008

Chroma Announces Positive Phase I Efficacy Data for Novel Cancer Therapy CHR-2797
13th December 2007

Chroma to Present Phase I Efficacy Data for Novel Cancer Therapy CHR-2797
30th November 2007

Chroma Progresses Novel Cancer Therapy CHR-2797 Into Phase II Solid Tumour Study
13th June 2007

Appointment of Klaus Veitinger as Non-Executive Director
22nd May 2007

CHR-2797 enters Phase II development
26th March 2007

Chroma raises $53m in Series C financing
3rd April 2006

Discovery Partners International, Inc. and Chroma Therapeutics Enter Into Collaboration For Lead Identification On Multiple Targets
25th March 2005

Chroma Therapeutics Ltd completes further financing round; raises £5m from major US healthcare investor
7th December 2004

First patient treated in Phase I study of CHR-2797 in cancer
16th November 2004

Chroma Therapeutics Ltd further strengthens its Management Team with the appointments of Chief Financial Officer and Chief Medical Officer
21st October 2004

Chroma Therapeutics Ltd completes £10m Series B financing and announces appointment of Peter Allen and Petri Vainio as non executive directors
14th June 2004

Appointment of Ian Nicholson as Chief Executive and Raj Parekh as Chairman
11th May 2004